Acute Myeloid Leukemia Market Share & Growth | Forecast 2031

Acute Myeloid Leukemia Market Share & Growth | Forecast 2031

Segments - Acute Myeloid Leukemia Market by Chemotherapy (Cytarabine and Anthracycline Drugs [Daunomycin, Idarubicin, and Mitoxantrone], Alkylating Agents, Anti-metabolites, and Tyrosine Kinase Inhibitors [Dasatinib (Sprycel) and Imatinib (Gleevec)], and Hormonal Therapy and Other Chemotherapies) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023-2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-1820 | 4.7 Rating | 70 Reviews | 170 Pages | Format : PDF Excel PPT

Report Description


Acute Myeloid Leukemia Market Outlook 2031:

The acute myeloid leukemia market size was valued at USD 1.51 Billion in 2022 and is projected to reach USD 3.60 Billion by 2031, expanding at a CAGR of 10.15% during the forecast period 2023 - 2031The growth of the market is attributed to high incidence of acute myeloid leukemia and relapses across the globe. Moreover, advancements in pharmacology and molecular biology to promote drug development is driving the market growth.

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia or acute non-lymphocytic leukemia, is a type of leukemia that affects the white blood cells. Acute myeloid leukemia is characterized by the rapid production of abnormal white blood cells, which accumulate in the bone marrow and disrupt the production of normal blood cells.

Acute Myeloid Leukemia Market Outlook


Increasing cases of AML is attributed to factors such as genetic mutations, unhealthy lifestyle, and continues exposure to hazardous chemicals such as benzene. Current drug therapies for AML are predicted, resulting in a demand for effective therapies, which is propelling the market growth. Some of the limitations of drugs available in the market includes their inability to control relapse cases and adverse side effects such as nausea, loss of appetite, and tissue damage.

The introduction of medicines such as farnesyltransferase inhibitors, immunotoxins, alkylating drugs, monoclonal antibodies, FMS-like tyrosine kinase 3 inhibitors, and multidrug-resistant modulators are fueling the market growth.

  • Rising demand for advanced therapeutics in the cancer treatment is a major driving force in the market.
  • Increasing R&D investments by pharmaceutical companies is expected to fuel the growth of the market.
  • The lack of efficacy of the medicine can restrain the market growth.
  • Technology-assisted drug development is anticipated to positively influence the market growth.

Scope of Acute Myeloid Leukemia Market Report

The report on the acute myeloid leukemia market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Acute Myeloid Leukemia Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

Chemotherapy (Cytarabine and Anthracycline Drugs [Daunomycin, Idarubicin, and Mitoxantrone], Alkylating Agents, Anti-metabolites, and Tyrosine Kinase Inhibitors [Dasatinib (Sprycel) and Imatinib (Gleevec)], and Hormonal Therapy and Other Chemotherapies)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Novartis AG, Teva Pharmaceuticals, Pfizer, Bristol Myer Squibb, and Sanofi-Aventis (Genzyme Corporation)

Acute Myeloid Leukemia Market Segment Insights:

Cytarabine and anthracycline drugs segment to account a significant market share

Based on types, the acute myeloid leukemia market is segregated into cytarabine and anthracycline drugs, alkylating agents, anti-metabolites, and tyrosine kinase inhibitors, and hormonal therapy and other chemotherapies. The cytarabine and anthracycline drugs segment is sub-segmented into daunomycin, idarubicin, and mitoxantrone.

This segment is estimated to hold a major market share and is anticipated to expand at a CAGR of 14% during the forecast period. Cytarabine (cytosine arabinoside (ara-C)) is a chemotherapy drug used to treat AML, acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML), and Non-Hodgkin lymphoma.


Anthracyclines are a class of drugs derived from the Streptomyces bacterium that are used in cancer chemotherapy. These compounds are used to treat a variety of cancers, including leukemia, lymphomas, breast cancer, stomach cancer, uterine cancer, ovarian cancer, bladder cancer, and lung cancer.

Acute Myeloid Leukemia Market Types

North America is projected to hold a major market share

In terms of regions, the acute myeloid leukemia market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market and is expected to expand at a rapid pace in the projected timeline. The presence of the prominent healthcare system in the US and Canada is driving the market growth in the region.

On the other hand, the market in Asia Pacific to exhibit a high CAGR during the forecast period. Rising investments, increasing disposable income, growing cancer awareness, and improved healthcare infrastructure are driving the regional market growth. Furthermore, increasing preference for therapies such as targeted therapies, which result in less collateral damage and higher efficacy, is expected to drive demand for the market in this region.

Acute Myeloid Leukemia Market Region

Segments

The acute myeloid leukemia market is segmented on the basis of

Types

  • Cytarabine and Anthracycline Drugs
    • Daunomycin
    • Idarubicin
    • Mitoxantrone
  • Alkylating Agents, Anti-metabolites, and Tyrosine Kinase Inhibitors
    • Dasatinib (Sprycel)
    • Imatinib (Gleevec)
  • Hormonal Therapy and Other Chemotherapies

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

Competitive Landscape

The major players in the acute myeloid leukemia market include Novartis AG, Teva Pharmaceuticals, Pfizer, Bristol Myer Squibb, and Sanofi-Aventis (Genzyme Corporation).

Companies are engaging in mergers, acquisitions, and partnerships to expand their market share. In order to gain a larger market share, these companies conduct extensive clinical trials, invest heavily in R&D, and target specific geographic areas.

Acute Myeloid Leukemia Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Acute Myeloid Leukemia Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Acute Myeloid Leukemia Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Acute Myeloid Leukemia Market - Supply Chain
  4.5. Global Acute Myeloid Leukemia Market Forecast
     4.5.1. Acute Myeloid Leukemia Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Acute Myeloid Leukemia Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Acute Myeloid Leukemia Market Absolute $ Opportunity
5. Global Acute Myeloid Leukemia Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Acute Myeloid Leukemia Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Acute Myeloid Leukemia Demand Share Forecast, 2019-2026
6. North America Acute Myeloid Leukemia Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Acute Myeloid Leukemia Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Acute Myeloid Leukemia Demand Share Forecast, 2019-2026
7. Latin America Acute Myeloid Leukemia Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Acute Myeloid Leukemia Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Acute Myeloid Leukemia Demand Share Forecast, 2019-2026
8. Europe Acute Myeloid Leukemia Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Acute Myeloid Leukemia Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Acute Myeloid Leukemia Demand Share Forecast, 2019-2026
9. Asia Pacific Acute Myeloid Leukemia Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Acute Myeloid Leukemia Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Acute Myeloid Leukemia Demand Share Forecast, 2019-2026
10. Middle East & Africa Acute Myeloid Leukemia Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Acute Myeloid Leukemia Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Acute Myeloid Leukemia Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Acute Myeloid Leukemia Market: Market Share Analysis
  11.2. Acute Myeloid Leukemia Distributors and Customers
  11.3. Acute Myeloid Leukemia Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Novartis AG Teva Pharmaceuticals Pfizer Bristol Myer Squibb Sanofi-aventis (Genzyme Corporation)

Methodology

Our Clients

Pfizer
FedEx Logistics
sinopec
Honda Motor Co. Ltd.
The John Holland Group
General Electric
Deloitte
Siemens Healthcare